γ-secretase modulators: Can we combine potency with safety?

International Journal of Alzheimer's Disease

Volumn , Issue , 2012, Pages

  Gijsen, Harrie J M ^a   Mercken, Marc ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; E 2012; E 2212; EVP 0926; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; JNJ 40418677; JNJ 42601572; SEMAGACESTAT; TARENFLURBIL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; DOSE RESPONSE; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; LIPOPHILICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE;

EID: 84872154160     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.1155/2012/295207     Document Type: Article

References (46)

1. Alzheimer's Association, 2012 Alzheimer's disease facts and figures. Alzheimer's and Dementia 2012 8 131 168
2. Hardy J., Selkoe D. J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002 297 5580 353 356 2-s2.0-0037135111 10.1126/science.1072994 (Pubitemid 34790756)
3. De Strooper B., Vassar R., Golde T., The secretases: enzymes with therapeutic potential in Alzheimer disease. Nature Reviews Neurology 2010 6 2 99 107 2-s2.0-76849086405 10.1038/nrneurol.2009.218
4. Varghese J., BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease 2010 Hoboken, NJ, USA John Wiley & Sons
5. Kreft A. F., Martone R., Porte A., Recent advances in the identification of γ -secretase inhibitors to clinically test the A β oligomer hypothesis of Alzheimer's disease. Journal of Medicinal Chemistry 2009 52 20 6169 6188 2-s2.0-70350059834 10.1021/jm900188z
6. D'Onofrio G., Panza F., Frisardi V., Solfrizzi V., Imbimbo B. P., Paroni G., Cascavilla L., Seripa D., Pilotto A., Advances in the identification of γ -secretase inhibitors for the treatment of Alzheimer's disease. Expert Opinion on Drug Discovery 2012 7 1 19 37 10.1517/17460441.2012.645534
7. Weggen S., Eriksen J. L., Das P., Sagi S. A., Wang R., Pietrzik C. U., Findlay K. A., Smith T. E., Murphy M. P., Bulter T., Kang D. E., Marquez-Sterling N., Golde T. E., Koo E. H., A subset of NSAIDs lower amyloidogenic A β 42 independently of cyclooxygenase activity. Nature 2001 414 6860 212 216 2-s2.0-0035829592 10.1038/35102591 (Pubitemid 33051236)
8. Eriksen J. L., Sagi S. A., Smith T. E., Weggen S., Das P., McLendon D. C., Ozols V. V., Jessing K. W., Zavitz K. H., Koo E. H., Golde T. E., NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo. Journal of Clinical Investigation 2003 112 3 440 449 2-s2.0-0042888943 10.1172/JCI200318162 (Pubitemid 38063773)
9. Imbimbo B. P., Why did tarenflurbil fail in alzheimer's disease? Journal of Alzheimer's Disease 2009 17 4 757 760 2-s2.0-68049148021 10.3233/JAD-2009- 1092
10. Cheng S., Comer D. D., Mao L., Balow G. P., Pleynet D., Aryl compounds and uses in modulating amyloid β WO 2004 2004110350
11. Nagy C., Schuck E., Ishibashi A., Nakatani Y., Rege B., Logovinsky V., E2012, a novel gamma-secretase modulator, decreases plasma amyloid-beta (A β) levels in humans. Journal of Alzheimer's Disease 2010 6 4 S574
12. Zettl H., Weggen S., Schneider P., Schneider G., Exploring the chemical space of γ -secretase modulators. Trends in Pharmacological Sciences 2010 31 9 402 410 2-s2.0-77956187227 10.1016/j.tips.2010.05.007
13. Oehlrich D., Berthelot D. J. C., Gijsen H. J. M., γ -Secretase modulators as potential disease modifying anti-Alzheimer's drugs. Journal of Medicinal Chemistry 2011 54 3 669 698 2-s2.0-79851473226 10.1021/jm101168r
14. Hopkins A. L., Groom C. R., Alex A., Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 2004 9 10 430 431 2-s2.0-1942453243 10.1016/S1359-6446(04)03069-7 (Pubitemid 38510559)
15. Bischoff F., Berthelot D., De Cleyn M., MacDonald G., Minne G., Oehlrich D., Pieters S., Surkyn M., Tresadern G., Van Brandt S., Velter I., Zaja M., Borghys H., Masungi C., Mercken M., Gijsen H. J. M., Design and synthesis of a novel series of bicyclic heterocycles as potent gamma;-secretase modulators. Journal of Medicinal Chemistry 2012 55 21 9089 9106 10.1021/jm201710f
16. Van Broeck B., Chen J. M., Tréton G., Desmidt M., Hopf C., Ramsden N., Karran E., Mercken M., Rowley A., Chronic treatment with a novel γ -secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. British Journal of Pharmacology 2011 163 2 375 389 2-s2.0-79954480259 10.1111/j.1476-5381.2011.01207.x
17. Borghys H., Tuefferd M., Van Broeck B., Clessens E., Dillen L., Cools W., Vinken P., Straetemans R., De Ridder F., Gijsen H., Mercken M., A canine model to evaluate efficacy and safety of γ -secretase inhibitors and modulators. Journal of Alzheimer's Disease 2012 28 4 809 822 10.3233/JAD-2011-111475
18. Imbimbo B. P., Del Giudice E., Cenacchi V., Volta R., Villetti G., Facchinetti F., Riccardi B., Puccini P., Moretto N., Grassi F., Ottonello S., Leon A., In vitro and in vivo profiling of CHF5022 and CHF5074. Two β -amyloid1-42 lowering agents. Pharmacological Research 2007 55 4 318 328 2-s2.0-34047202594 10.1016/j.phrs.2006.12.010 (Pubitemid 46533934)
19. Peng H., Talreja T., Xin Z., Cuervo J. H., Kumaravel G., Humora M. J., Xu L., Rohde E., Gan L., Jung M.-Y., Shackett M. N., Chollate S., Discovery of BIIB042, a potent, selective, and orally bioavailable γ -secretase modulator. ACS Medicinal Chemistry Letters 2011 2 10 786 791 10.1021/ml200175q
20. Hall A., Elliott R. L., Giblin G. M. P., Hussain I., Musgrave J., Naylor A., Sasse R., Smith B., Piperidine-derived γ -secretase modulators. Bioorganic and Medicinal Chemistry Letters 2010 20 3 1306 1311 2-s2.0-74049139969 10.1016/j.bmcl.2009.08.072
21. Stanton M. G., Hubbs J., Sloman D., Hamblett C., Andrade P., Angagaw M., Bi G., Black R. M., Crispino J., Cruz J. C., Fan E., Farris G., Hughes B. L., Kenific C. M., Middleton R. E., Nikov G., Sajonz P., Shah S., Shomer N., Szewczak A. A., Tanga F., Tudge M. T., Shearman M., Munoz B., Fluorinated piperidine acetic acids as γ -secretase modulators. Bioorganic and Medicinal Chemistry Letters 2010 20 2 755 758 2-s2.0-72249100345 10.1016/j.bmcl.2009.11.034
22. Kounnas M. Z., Danks A. M., Cheng S., Tyree C., Ackerman E., Zhang X., Ahn K., Nguyen P., Comer D., Mao L., Yu C., Pleynet D., Digregorio P. J., Velicelebi G., Stauderman K. A., Comer W. T., Mobley W. C., Li Y. M., Sisodia S. S., Tanzi R. E., Wagner S. L., Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 2010 67 5 769 780 2-s2.0-77956311201 10.1016/j.neuron.2010.08.018
23. Hashimoto T., Ishibashi A., Hagiwara H., Murata Y., Takenaka O., Miyagawa T., E2012: a novel gamma-secretase modulator; pharmacology part. Alzheimer's & Dementia 2010 6 4 S242
24. Wan Z., Hall A., Jin Y., Xiang J. N., Yang E., Eatherton A., Smith B., Yang G., Yu H., Wang J., Ye L., Lau L. F., Yang T., Mitchell W., Cai W., Zhang X., Sang Y., Wang Y., Tong Z., Cheng Z., Hussain I., Elliott J. D., Matsuoka Y., Pyridazine-derived γ -secretase modulators. Bioorganic and Medicinal Chemistry Letters 2011 21 13 4016 4019 2-s2.0-79958762976 10.1016/j.bmcl.2011. 04.143
25. Qin J., Zhou W., Huang X., Dhondi P., Palani A., Aslanian R., Zhu Z., Greenlee W., Cohen-Williams M., Jones N., Hyde L., Zhang L., Discovery of a potent pyrazolopyridine series of γ -secretase modulators. ACS Medicinal Chemistry Letters 2011 2 6 471 476 2-s2.0-79959223785 10.1021/ml2000438
26. Sun Z.-Y., Asberom T., Bara T., Bennett C., Burnett D., Chu I., Clader J., Cohen-Williams M., Cole D., Czarniecki M., Durkin J., Gallo G., Greenlee W., Josien H., Huang X., Hyde L., Jones N., Kazakevich I., Li H., Liu X., Lee J., MacCoss M., Mandal M. B., McCracken T., Nomeir A., Mazzola R., Palani A., Parker E. M., Pissarnitski D. A., Qin J., Song L., Terracina G., Vicarel M., Voigt J., Xu R., Zhang L., Zhang Q., Zhao Z., Zhu X., Zhu Z., Cyclic hydroxyamidines as amide isosteres: discovery of oxadiazolines and oxadiazines as potent and highly efficacious γ -secretase modulators in vivo. Journal of Medicinal Chemistry 2012 55 1 489 502 10.1021/jm201407j
27. Lübbers T., Flohr A., Jolidon S., Jacobsen H., Ozmen L., Baumann K., David-Pierson P., Aminothiazoles as γ -secretase modulators. Bioorganic and Medicinal Chemistry Letters 2011 21 21 6554 6558 10.1016/j.bmcl.2011.08.060
28. Pettersson M., Johnson D. S., Subramanyam C., Bales K. R., Am Ende C. W., Fish B. A., Green M. E., Kauffman G. W., Lira R., Mullins P. B., Navaratnam T., Sakya S. M., Stiff C. M., Tran T. P., Vetelino B. C., Xie L., Zhang L., Pustilnik L. R., Wood K. M., O'Donnell C. J., Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ -secretase modulators. Bioorganic and Medicinal Chemistry Letters 2012 22 8 2906 2911 10.1016/j.bmcl.2012.02.059
29. Meanwell N. A., Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chemical Research in Toxicology 2011 24 9 1420 1456 10.1021/tx200211v
30. Hann M. M., Keseü G. M., Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nature Reviews Drug Discovery 2012 11 5 355 365 10.1038/nrd3701
31. Hann M. M., Molecular obesity, potency and other addictions in drug discovery. Medicinal Chemistry Communications 2011 2 5 349 355 2-s2.0-79955613841 10.1039/c1md00017a
32. Lovering F., Bikker J., Humblet C., Escape from flatland: increasing saturation as an approach to improving clinical success. Journal of Medicinal Chemistry 2009 52 21 6752 6756 2-s2.0-71049126548 10.1021/jm901241e
33. Leeson P. D., Springthorpe B., The influence of drug-like concepts on decision-making in medicinal chemistry. Nature Reviews Drug Discovery 2007 6 11 881 890 2-s2.0-35748934487 10.1038/nrd2445 (Pubitemid 350042396)
34. Keserü G. M., Makara G. M., The influence of lead discovery strategies on the properties of drug candidates. Nature Reviews Drug Discovery 2009 8 3 203 212 2-s2.0-61649109015 10.1038/nrd2796
35. Tarcsay A., Nyíri K., Keserú G. M., Impact of lipophilic efficiency on compound quality. Journal of Medicinal Chemistry 2012 55 3 1252 1260 10.1021/jm201388p
36. Green R. C., Schneider L. S., Amato D. A., Beelen A. P., Wilcock G., Swabb E. A., Zavitz K. H., Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. Journal of the American Medical Association 2009 302 23 2557 2564 2-s2.0-72549105935 10.1001/jama.2009.1866
37. Wan H., Rehngren M., Giordanetto F., Bergström F., Tunek A., High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. Journal of Medicinal Chemistry 2007 50 19 4606 4615 2-s2.0-34648813134 10.1021/jm070375w (Pubitemid 47463235)
38. Karran E., Mercken M., Strooper B. D., The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature Reviews Drug Discovery 2011 10 9 698 712 10.1038/nrd3505
39. Probst G., Xu Y.-Z., Small-molecule BACE1 inhibitors: a patent literature review (2006-2011). Expert Opinion on Therapeutic Patents 2012 22 5 511 540 10.1517/13543776.2012.681302
40. Ohki Y., Higo T., Uemura K., Shimada N., Osawa S., Berezovska O., Yokoshima S., Fukuyama T., Tomita T., Iwatsubo T., Phenylpiperidine-type γ -secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO Journal 2011 30 23 4815 4824 10.1038/emboj.2011.372
41. Jumpertz T., Rennhack A., Ness J., Baches S., Pietrzik C. U., Bulic B., Weggen S., Presenilin is the molecular target of acidic γ -secretase modulators in living cells. PLoS ONE 2012 7 1 e30484 10.1371/journal.pone. 0030484
42. Ebke A., Luebbers T., Fukumori A., Shirotani K., Haass C., Baumann K., Steiner H., Novel γ -secretase enzyme modulators directly target presenilin protein. Journal of Biological Chemistry 2011 286 43 37181 37186 10.1074/jbc.C111.276972
43. Findeis M. A., Schroeder F., McKee T. D., Yager D., Fraering P. C., Creaser S. P., Austin W. F., Clardy J., Wang R., Selkoe D., Eckman C.B., Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the Extract of Actaea racemosa. ACS Chemical Neuroscience 2012 3 11 941 951
44. Hubbs J. L., Fuller N. O., Austin W. F., Shen R., Creaser S. P., McKee T. D., Loureiro R. M. B., Tate B., Xia W., Ives J., Bronk B. S., Optimization of a natural product-based class of gamma;-secretase modulators. Journal of Medicinal Chemistry 2012 55 21 9270 9282 10.1021/jm300976b
45. Chévez-Gutiérrez L., Bammens L., Benilova I., Vandersteen A., Benurwar M., Borgers M., Lismont S., Zhou L., Van Cleynenbreugel S., Esselmann H., Wiltfang J., Serneels L., Karran E., Gijsen H., Schymkowitz J., Rousseau F., Broersen K., De Strooper B., The mechanism of γ -Secretase dysfunction in familial Alzheimer disease. EMBO Journal 2012 31 10 2261 2274 10.1038/emboj.2012.79
46. De Strooper B., Annaert W., Novel research horizons for presenilins and γ -secretases in cell biology and disease. Annual Review of Cell and Developmental Biology 2010 26 235 260 2-s2.0-78049374467 10.1146/annurev- cellbio-100109-104117